Tesamorelin reconstitution protocol

This protocol describes the reconstitution and storage of lyophilized tesamorelin in standard research workflows. Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) — it's the only GHRH analog approved for clinical use, originally for HIV-associated lipodystrophy research. Values below are derived from published handling literature; experimental design parameters are the responsibility of the qualified investigator.

At a glance

Parameter	Value
Recommended diluent	Bacteriostatic Water (USP, 0.9% benzyl alcohol)
Recommended volume (10 mg vial)	2.0 mL
Final concentration	5 mg/mL
Stability — lyophilized	≥24 months at -20 °C, light-protected, sealed
Stability — reconstituted	14 days at 2–8 °C in original vial
Freeze-thaw	Avoid on reconstituted solution. Aliquot for extended storage.

Procedure

1. Equilibrate the vial to room temperature.
2. Sterile prep: wipe stopper with isopropyl, allow to dry. Use sterile syringe and 21G or larger needle.
3. Inject diluent slowly along the inner glass wall. Tesamorelin is moderately sensitive to mechanical stress during reconstitution.
4. Swirl gently. Do not shake. Cake dissolves within 30–60 seconds.
5. Verify: solution should be clear and colorless.

Compound notes

Tesamorelin is a 44-amino-acid analog of native GHRH, with a trans-3-hexenoyl modification at the N-terminus that increases resistance to dipeptidyl peptidase-4 (DPP-4) cleavage. This modification approximately doubles the in-vivo half-life compared to native GHRH while preserving full agonist activity at the GHRH receptor. The molecule still has a relatively short plasma half-life (~26 minutes) compared to the long-acting CJC-1295, so research protocols typically use daily administration in rodent models.

The reconstituted form is somewhat less stable than tirzepatide or BPC-157 in solution — plan for 14 days at refrigerated storage rather than the standard 30. Aliquot if you need a longer experimental window.

Storage

Reconstituted tesamorelin is stable for approximately 14 days at 2–8 °C. For longer storage, aliquot into sterile single-use tubes and freeze at -20 °C or colder. Lyophilized stability is ≥24 months at -20 °C light-protected.

Notes

This protocol describes reconstitution parameters from published compound-handling literature. It is not a recommendation for any specific study design. For research use only. Not for human or veterinary use.

References

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM 2007;357:2359–2370. PMID: 18057338
2. Stanley TL, Falutz J, Mamputu JC, et al. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat. AIDS 2011;25:1281–1288. PMID: 21516029